The first anti-PD-(L)1 antibody (nivolumab) was approved for advanced NSCLC in Japan in 2015, and the first TKI (gefitinib) was approved in 2002 [9,10]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.